Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients. Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones. Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight. In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of <100 Hounsfield units (values of <100 HU predict cholesterol rich, dissolvable stones). Gall bladder bile was obtained by ultrasound guided, fine needle puncture from six patients. All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 101-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (<4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling. Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.
Octreotide, a long acting analogue of somatostatin, suppresses both growth hormone and insulin like growth factor 1 secretion and is used to treat acromegaly. However, long term octreotide treatment induces gall bladder stones in 13-60% of patients after 3 to 51 months' treatment.1 2 Gall stones are conventionally classified as: (i) cholesterol rich stones (arbitrarily >70% cholesterol by weight: they may also contain variable amounts of calcium salts and bile pigments) and (ii) non-cholesterol stones -that is, brown pigment and black pigment stones. Anecdotal reports suggest that most gall stones found during octreotide treatment are radiolucent,3 4 presumed cholesterol rich, and dissolvable with oral bile acid therapy.3-5 There have been no systematic studies of the composition and dissolvability of gall stones found during octreotide treatment -essential information for studies of their pathogenesis, treatment, and prevention. We therefore studied stone composition in 14 octreotide treated acromegalic patients with gall stones using direct and indirect methods, including, in a subgroup of nine, stone dissolvability during oral bile acid therapy.
Patients and methods
Fourteen acromegalic patients (eight men), with a mean age of 52 years (range 25 to 66) were studied. They had been treated with a mean dose of 300 ,ug octreotide/day (range 150-600) for a mean duration of 19 months (range 3 to 36) before their gall stones were diagnosed by ultrasonography. At the time the stones were detected, none of the patients had symptoms related to gall stones. In one, a 43 year old woman, octreotide had been stopped for nine months after she had been treated for a total of three years. Three patients were shown to be free of stones by ultrasound before octreotide treatment began. They were found to have developed gall stones three, 12 , and 15 months after starting octreotide, and their stones were therefore classified as octreotide induced. In the remaining 11 , no imaging studies of the gall bladder had been carried out before octreotide treatment to exclude preexisting stones: they were, therefore, described as octreotide associated gall stones.
GALL STONE COMPOSITION
Gall stones, retrieved at cholecystectomy, were available for direct chemical analysis in two of 14 patients: in the remaining 12 , indirect methods of predicting stone composition were used: (i) localised computed tomography of the gall bladder and (ii) analysis of gall bladder bile.
Direct analysis of stone composition One acromegalic patient underwent elective cholecystectomy because of recurrent biliary colic. In the second, a sailor, the gall bladder was removed 'prophylactically' to prevent the remote chance6 of gall stone related complications while he was at sea.
The macroscopic appearance of the outer and cut surfaces of the stones (Fig 1) was noted and the stones were dried, weighed, and ground to a powder. The resultant powder was then alkalinised with 1% sodium bicarbonate and its cholesterol was extracted using chloroform:methanol (2:1 volume). The chloroform phase containing the cholesterol was separated from the methanol phase and evaporated to dryness in a rotary evaporator. The residue was then resolubilised in isopropanol, its cholesterol content was assayed enzymatically,7 and the results were expressed as a percentage of dry stone weight. dissolution response to oral therapy was therefore assessed in only nine patients. Moreover, one of these (no 12) emigrated after six months of treatment, although by that time his response to UDCA had already been assessed at the three and six month follow up visits.
If, after six months of UDCA therapy, there was no reduction in either the maximum stone diameter or number, or both, an oral cholecystogram was performed to exclude blockage of the cystic duct. In four of the five patients treated with oral bile acids for more than 12 months who had no ultrasound evidence of gall stone dissolution, a localised computed tomogram of the gall bladder was repeated to exclude acquired gall stone calcification. Furthermore, in four of these five patients a second oral cholecystogram was carried out after 16-20 months of UDCA treatment. In the fifth, who became intolerant or oral contrast media, a 99mTc-HIDA (99mtech-netium-labelled diethyl hydroxyimino diacetic acid) radionucleotide scan was performed to assess cystic duct patency.
Partial gall stone dissolution was defined as a reduction in stone number or diameter of at least 50%. Complete gall stone dissolution was accepted only after two consecutive ultrasound scans of the gall bladder, one month apart during continued oral UDCA treatment, confirmed the absence of stones.
UDCA treatment was stopped for any one of the following three reasons: (i) when complete gall stone dissolution was confirmed, (ii) if patients were found to have developed a blocked cystic duct; or (iii) if stones had not dissolved completely after 24 months' therapy. ETHICAL 
CONSIDERATIONS
The use of ultrasound guided, fine needle puncture of the gall bladder was approved by the Research Ethics Committee of St Bartholomew's Hospital and by the Ethics Committee of Guy's Hospital. All patients gave their written informed consent.
Results
The results for stone composition and the response to oral bile acid therapy are given in the Table. STONE COMPOSITION Direct analysis Both of the patients who underwent cholecystectomy had multiple, smooth, faceted gall stones. The cut surface of both sets of stones showed a pigmented centre with a surrounding lattice of radiating 'spokes' of cholesterol crystals (Fig 1) . Direct chemical analysis of the stones showed that they contained 71% and 87% cholesterol by weight, respectively. 01-1-53) .
Indirect analysis
In the four patients in whom biliary cholesterol microcrystals were seen, the nucleation time was invariably short (one day) and the maximum computed tomography attenuation scores were all < 100 HU 
DISSOLVABILITY OF GALL STONES WITH ORAL BILE ACID THERAPY
The overall outcome of UDCA treatment in the 12 acromegalic patients with octreotide associated gall stones who were considered for oral bile acids, is summarised in Figure 3 . The gall stone dissolution response (partial and complete), as calculated by actuarial or life table analysis, is shown in Figure 4 .
As the results in Figure 3 show, complete gall stone dissolution was seen in two (nos 10 and 11) of the nine patients (22.2%), after three and four months UDCA therapy respectively. One of these (no 11) had stopped octreotide nine months before starting UDCA treatment. In the second, the induced gall stones dissolved with oral UDCA despite continued octreotide therapy.
Partial stone dissolution occurred in three patients (33-3%) after 6 to 12 months UDCA. As noted above (see 'Treatment and follow up' in the Methods section), one of these (no 12) was lost to follow up after six months. A second (no 8), who had complained of biliary colic some nine months after starting UDCA, was found to have developed a blocked cystic duct at 21 months, while the third (no 9) had calcified stones before UDCA treatment began (computed tomography score 490 HU).
In the remaining four patients (44A4% 
Discussion
These results show that in most patients with octreotide induced/associated gall stones, the stones are small, multiple, and cholesterol rich. However, unlike earlier reports,34 the stones in one third of our patients were dense on computed tomography (attenuation scores of >100 HU) suggesting that they contained more than 3%/o calcium by weight.28 Moreover, before UDCA treatment, 17% of the patients reported here had a blocked cystic duct -a figure comparable to that found in epidemiological screening studies of the general (nonacromegalic) population. 29 Despite the suggestion that octreotide associated gall stones should dissolve with oral bile acids, [3] [4] [5] we found that during UDCA treatment, only two patients (22%) showed complete gall stone dissolution.
STUDY DESIGN
Only three of our 14 patients had octreotide induced, as opposed to octreotide associated, gall stones. In theory, therefore, some of the remaining 11 could have had stones which antedated the octreotide treatment. In practice, this seems unlikely since the prevalence of stones in octreotide treated acromegalic patientsl 2 is much higher than that in their counterparts who are not treated with octreotide.5 30 31 Indeed, in the same cohort of acromegalic patients as that studied here, 50% of those treated with octreotide were found to have gall stones. This compares with a prevalence of only 15% in untreated acromegaly -a figure which is not significantly criterionfor success is a symptom free patient with complete gall stone dissolution.
DIRECT CHEMICAL ANALYSIS OF OCTREOTIDE INDUCED GALL STONES
Based on our arbitrary definition (see above), both sets of octreotide induced gall stones retrieved at cholecystectomy were cholesterol rich (>70% cholesterol by weight). Despite this, 13% and 29% respectively of these stones comprised material that was not cholesterol, and although we did not assay the stones for calcium or bilirubin, the macroscopic appearance of their cut surface showed a pigment rich centre. These appearances are common in conventional gall stone disease, where the nucleus consists of calcium bilirubinate and other calcium salts.34 Furthermore, four of the 12 acromegalic patients studied by localised computed tomography, had stones with attenuation scores of >100 HU, suggesting that they were either non-cholesterol in type or contained more than 3% calcium salts.28
INDIRECT ASSESSMENT OF STONE COMPOSITION Attenuation scores
In our experiencel' and that of others,35 a computed tomography attenuation score < 100 HU predicts cholesterol rich stones which dissolve well with oral bile acid therapy. Of the four acromegalics with stones shown to be dense by computed tomography, only one also had a pretreatment ultrasound (to exclude gall stones before octreotide treatment). Thus, it remains possible that those with the highest computed tomography scores had pre-existing stones. The other two patients with octreotide induced gall stones had not undergone computed tomography before cholecystectomy.
In this series, the prevalence of stones that looked dense on computed tomography is 'CT-dense' stones in the general gall stone population but, based on previous observations,89 one would expect this to be higher than 30%.
Bile composition All six bile samples studied were supersaturated with cholesterol. This observation is compatible with the suggestion that these octreotide associated stones were rich in cholesterol. The Complete or partial stone dissolution occurred in five of nine patients treated with UDCA in whom follow up was possible, which suggests that at least part of these stones was composed of cholesterol. The complete stone dissolution rate in this study is similar to that in 126 patients without acromegaly, but with radiolucent stones, treated with UDCA in another study from our unit.38
Failure to dissolve stones completely with oral bile acid therapy may be due to: (i) an inadequate dose of bile acids; (ii) an adequate dose but poor patient compliance in taking the prescribed medication; (iii) despite adequate doses and a compliant patient, failure of the oral bile acids desaturate bile (cholesterol saturation index <1-0); (iv) the development, during treatment, of cystic duct blockage; (v) acquired stone calcification; and (vi) the presence of stones which, before treatment, were lucent by both conventional radiology and computed tomography, but were none the less non-cholesterol in type.
In the present study, all nine patients were given 10 mg UDCA/kg/day -the optimum dose for stone dissolution in patients of normal weight39 -and claimed to have taken their oral UDCA regularly. Two non-cholesterol stones. Because of this, the best indirect criteria for predicting stone composition are the presence of biliary microcrystals and rapid nucleation time. Four of the six patients who underwent biliary analysis had both cholesterol microcrystals and rapid nucleation, thus predicting that at least 67% of stones associated with octreotide treatment are cholesterol rich.
We conclude that octreotide induced/associated gall stones are generally small, multiple, and cholesterol rich. Although inhibition of meal stimulated CCK release, leading to gall bladder stasis,2 has been implicated in stone formation, we have shown elsewhere37 that gall bladder bile from acromegalic patients with octreotide associated stones is also: (i) supersaturated with cholesterol; (ii) rich in vesicular cholesterol; (iii) has a high vesicular cholesterol: phospholipid molar ratio; and (iv) nucleates rapidly to form cholesterol microcrystals -important defects in the pathogenesis of 'conventional' cholesterol gall stones in patients who do not have agromegaly. Finally, in common with spontaneous gall stone disease, some of the acromegalic patients with octreotide associated gall stones have a blocked cystic duct or stones which are contaminated with calcium.
